SEC Form 4 · accession 0001104659-16-108197

Corvus Pharmaceuticals, Inc. · CRVS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Financial Officer

Period of report

Mar 29, 2016

Accepted (ET)

Mar 29, 2016 · 11:42 am EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001626971

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, $0.0001 par value^F1,F2,F3	Mar 29, 2016	C	42,608	—	A	199,253	I	By Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Preferred Stock^F1,F3,F4	—	Mar 29, 2016	C	42,608	D	—	—	Common Stock	42,608	0	I

F1The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering.
F2A portion of these shares is subject to a right of repurchase held by the Issuer.
F3These shares are held by Leiv Lea and Deborah Karlson, Trustees of the Karlson Lea Family Trust UTA dated February 11, 1998 (the "Karlson Lea Trust"). Mr. Lea has shared voting, investment and dispositive power over the shares held by the Karlson Lea Trust.
F4The expiration date is not relevant to the conversion of these securities.